{"id":746070,"date":"2019-03-05T06:45:00","date_gmt":"2019-03-05T06:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-immune-design\/"},"modified":"2025-05-12T08:58:17","modified_gmt":"2025-05-12T12:58:17","slug":"merck-begins-tender-offer-to-acquire-immune-design","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-immune-design\/","title":{"rendered":"Merck Begins Tender Offer to Acquire Immune Design"},"content":{"rendered":"<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada, is<br \/>\n      commencing today, through a subsidiary, a cash tender offer to purchase<br \/>\n      all outstanding shares of common stock of Immune Design (NASDAQ: IMDZ).<br \/>\n      On Feb. 21, 2019, Merck announced its intent to acquire Immune Design.\n    <\/p>\n<p>\n      Upon the successful closing of the tender offer, stockholders of Immune<br \/>\n      Design will receive $5.85 in cash for each share of Immune Design common<br \/>\n      stock validly tendered and not validly withdrawn in the offer, without<br \/>\n      interest and less any required withholding taxes. Following the purchase<br \/>\n      of shares in the tender offer, Immune Design will become a wholly-owned<br \/>\n      subsidiary of Merck.\n    <\/p>\n<p>\n      Merck will file today with the U.S. Securities and Exchange Commission<br \/>\n      (SEC) a tender offer statement on Schedule TO, which provides the terms<br \/>\n      of the tender offer. Additionally, Immune Design will file with the SEC<br \/>\n      a solicitation\/recommendation statement on Schedule 14D-9 that includes<br \/>\n      the recommendation of the Immune Design board of directors that their<br \/>\n      stockholders accept the tender offer and tender their shares.\n    <\/p>\n<p>\n      The tender offer will expire at 12:00 am EDT on April 2, 2019, unless<br \/>\n      extended in accordance with the merger agreement and the applicable<br \/>\n      rules and regulations of the SEC. The closing of the tender offer is<br \/>\n      subject to customary terms and conditions, including the tender of a<br \/>\n      number of shares which, together with shares then owned by Merck (if<br \/>\n      any), represents a majority of the outstanding shares, and the<br \/>\n      expiration or the termination of the waiting period under the<br \/>\n      Hart-Scott-Rodino Antitrust Improvements Act. The transaction is<br \/>\n      expected to close early in the second quarter of 2019.\n    <\/p>\n<p>\n      <b>Additional Information about the Tender Offer<\/b>\n    <\/p>\n<p>\n      This press release is for informational purposes only and is neither an<br \/>\n      offer to purchase nor a solicitation of an offer to sell any shares of<br \/>\n      the common stock of Immune Design (\u201cIMDZ\u201d) or any other securities. A<br \/>\n      tender offer statement on Schedule TO, including an offer to purchase, a<br \/>\n      letter of transmittal and related documents, will be filed by Merck<br \/>\n      Sharp &amp; Dohme Corp. (\u201c<span class=\"bwuline\">Merck<\/span>\u201d) and<br \/>\n      Cascade Merger Sub Inc., a wholly-owned subsidiary of Merck (\u201c<span class=\"bwuline\">Buyer<\/span>\u201d),<br \/>\n      with the Securities and Exchange Commission (the \u201c<span class=\"bwuline\">SEC<\/span>\u201d),<br \/>\n      and a solicitation\/recommendation statement on Schedule 14D-9 will be<br \/>\n      filed by Immune Design with the SEC. The offer to purchase shares of<br \/>\n      Immune Design common stock will only be made pursuant to the offer to<br \/>\n      purchase, the letter of transmittal and related documents filed as a<br \/>\n      part of the Schedule TO.\n    <\/p>\n<p>\n      <b>INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER<br \/>\n      OFFER STATEMENT AND THE SOLICITATION\/RECOMMENDATION STATEMENT REGARDING<br \/>\n      THE OFFER, AS THEY MAY BE AMENDED FROM TIME TO TIME, WHEN THEY BECOME<br \/>\n      AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.<\/b>\n    <\/p>\n<p>\n      Investors and security holders may obtain a free copy of these<br \/>\n      statements (when available) and other documents filed with the SEC at<br \/>\n      the website maintained by the SEC at <a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a><br \/>\n      or by directing such requests to the Information Agent for the Offer,<br \/>\n      which will be named in the tender offer statement. Additional copies of<br \/>\n      the tender offer materials may be obtained at no charge by contacting<br \/>\n      Merck at 2000 Galloping Hill Road, Kenilworth, N.J., 07033 or by phoning<br \/>\n      (908) 423-1000. In addition, Merck and Immune Design file annual,<br \/>\n      quarterly and current reports and other information with the SEC. You<br \/>\n      may read and copy any reports or other information filed by Merck or<br \/>\n      Immune Design at the SEC public reference room at 100 F Street, N.E.,<br \/>\n      Washington, D.C., 20549. For further information on the SEC public<br \/>\n      reference room, please call 1-800-SEC-0330. Merck\u2019s and Immune Design\u2019s<br \/>\n      filings with the SEC are also available to the public from commercial<br \/>\n      document-retrieval services and at the SEC\u2019s website at <a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"https:\/\/www.youtube.com\/user\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d that are based upon the<br \/>\n      current beliefs and expectations of the company\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, risks associated<br \/>\n      with the ability to consummate the proposed transaction described<br \/>\n      herein; general industry conditions and competition; general economic<br \/>\n      factors, including interest rate and currency exchange rate<br \/>\n      fluctuations; the impact of pharmaceutical industry regulation and<br \/>\n      health care legislation in the United States and internationally; global<br \/>\n      trends toward health care cost containment; technological advances, new<br \/>\n      products and patents attained by competitors; challenges inherent in new<br \/>\n      product development, including obtaining regulatory approval; the<br \/>\n      company\u2019s ability to accurately predict future market conditions;<br \/>\n      manufacturing difficulties or delays; financial instability of<br \/>\n      international economies and sovereign risk; dependence on the<br \/>\n      effectiveness of the company\u2019s patents and other protections for<br \/>\n      innovative products; and the exposure to litigation, including patent<br \/>\n      litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2018 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>)\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media Contacts:<br \/>Pamela Eisele<br \/>(267) 305-3558<\/p>\n<p>Investor        Contacts:<br \/>Peter Dannenbaum<br \/>(908) 740-1037<\/p>\n<p>Courtney        Ronaldo<br \/>(908) 740-6132     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Immune Design (NASDAQ: IMDZ). On Feb. 21, 2019, Merck announced its intent to acquire Immune Design. Upon the successful closing of the tender offer, stockholders of Immune Design will receive $5.85 in cash for each share of Immune Design common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. Following the purchase of shares in the tender offer, Immune Design will become a wholly-owned subsidiary of Merck. Merck will file today with the U.S. Securities and Exchange Commission (SEC) a tender offer statement on Schedule TO, which provides the terms of the tender offer. Additionally, Immune Design will file with the SEC a solicitation\/recommendation statement on Schedule 14D-9 that includes the recommendation of the Immune Design<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-746070","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Begins Tender Offer to Acquire Immune Design - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-immune-design\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Begins Tender Offer to Acquire Immune Design - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Immune Design (NASDAQ: IMDZ). On Feb. 21, 2019, Merck announced its intent to acquire Immune Design. Upon the successful closing of the tender offer, stockholders of Immune Design will receive $5.85 in cash for each share of Immune Design common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. Following the purchase of shares in the tender offer, Immune Design will become a wholly-owned subsidiary of Merck. Merck will file today with the U.S. Securities and Exchange Commission (SEC) a tender offer statement on Schedule TO, which provides the terms of the tender offer. Additionally, Immune Design will file with the SEC a solicitation\/recommendation statement on Schedule 14D-9 that includes the recommendation of the Immune Design\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-immune-design\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:58:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-immune-design\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-immune-design\\\/\",\"name\":\"Merck Begins Tender Offer to Acquire Immune Design - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-immune-design\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-immune-design\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-03-05T06:45:00+00:00\",\"dateModified\":\"2025-05-12T12:58:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-immune-design\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-immune-design\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-immune-design\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-begins-tender-offer-to-acquire-immune-design\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Begins Tender Offer to Acquire Immune Design\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Begins Tender Offer to Acquire Immune Design - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-immune-design\/","og_locale":"en_US","og_type":"article","og_title":"Merck Begins Tender Offer to Acquire Immune Design - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Immune Design (NASDAQ: IMDZ). On Feb. 21, 2019, Merck announced its intent to acquire Immune Design. Upon the successful closing of the tender offer, stockholders of Immune Design will receive $5.85 in cash for each share of Immune Design common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. Following the purchase of shares in the tender offer, Immune Design will become a wholly-owned subsidiary of Merck. Merck will file today with the U.S. Securities and Exchange Commission (SEC) a tender offer statement on Schedule TO, which provides the terms of the tender offer. Additionally, Immune Design will file with the SEC a solicitation\/recommendation statement on Schedule 14D-9 that includes the recommendation of the Immune Design","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-immune-design\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:58:17+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-immune-design\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-immune-design\/","name":"Merck Begins Tender Offer to Acquire Immune Design - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-immune-design\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-immune-design\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-03-05T06:45:00+00:00","dateModified":"2025-05-12T12:58:17+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-immune-design\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-immune-design\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-immune-design\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-begins-tender-offer-to-acquire-immune-design\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Begins Tender Offer to Acquire Immune Design"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"53be6b18-8c59-4c5b-a8ab-29b89de64e09","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Begins-Tender-Offer-to-Acquire-Immune-Design-2019.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746070\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=746070"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=746070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}